People with Parkinson’s disease who experience digestive issues or probable rapid eye movement (REM) sleep behavior disorder may be…
Articles by Margarida Maia, PhD
Having irritable bowel syndrome (IBS), a gastrointestinal disorder that may be linked to how the brain and gut communicate with…
SPARX3, an ongoing clinical trial investigating the effects of moderate– and high-intensity aerobic exercise —…
The first patients received doses of an oral thin-film formulation of montelukast in a clinical trial testing the treatment’s potential…
The presence of salt or a molecular crowd may make it more likely for the alpha-synuclein protein, which forms toxic…
People with Parkinson’s disease are nearly twice as likely to experience delirium during hospital stays as hospitalized older adults…
NeuroOne has begun a limited U.S. commercial launch of its OneRF Ablation System, a device that can be…
BioVie is planning to launch in late summer a Phase 2b clinical trial of NE3107, its investigational anti-inflammatory small molecule,…
Monte Rosa Therapeutics is running preclinical studies testing MRT-8102, an orally available molecular glue degrader that targets NEK7, a…
An antibody that targets a naturally occurring modified form of alpha-synuclein, a protein that forms into toxic clumps in the…